{"version":3,"file":"component---src-pages-silo-2-js-a746b34d0799ac592289.js","mappings":"40HAKe,SAASA,IACtB,OACEC,EAAAA,cAACC,EAAAA,EAAM,KACLD,EAAAA,cAAA,OAAKE,UAAU,4BACbF,EAAAA,cAAA,WAASE,UAAU,gBACjBF,EAAAA,cAAA,OAAKE,UAAU,aACbF,EAAAA,cAAA,UAAI,kEACJA,EAAAA,cAAA,SAAG,wQAMHA,EAAAA,cAAA,KAAGE,UAAU,gBAAe,8IAOhCF,EAAAA,cAAA,WAASE,UAAU,WACjBF,EAAAA,cAAA,MAAIE,UAAU,iBAAgB,kDAC9BF,EAAAA,cAAA,SAAG,mDAEHA,EAAAA,cAAA,UAAI,gCACJA,EAAAA,cAAA,SAAG,yPAMHA,EAAAA,cAAA,UAAI,gCACJA,EAAAA,cAAA,SAAG,0EACHA,EAAAA,cAAA,MAAIE,UAAU,cACZF,EAAAA,cAAA,UAAI,+EACJA,EAAAA,cAAA,UAAI,oFACJA,EAAAA,cAAA,UAAI,uFACJA,EAAAA,cAAA,UAAI,+EACJA,EAAAA,cAAA,UAAI,wEAGNA,EAAAA,cAAA,UAAI,iCACJA,EAAAA,cAAA,SAAG,gQAMHA,EAAAA,cAAA,UAAI,cACJA,EAAAA,cAAA,SAAG,4NAOLA,EAAAA,cAAA,WAASE,UAAU,WACjBF,EAAAA,cAAA,MAAIE,UAAU,iBAAgB,oDAC9BF,EAAAA,cAAA,SAAG,6GAKHA,EAAAA,cAAA,UAAI,gDACJA,EAAAA,cAAA,OAAKE,UAAU,wBACbF,EAAAA,cAACG,EAAAA,EAAW,CACVC,IAAI,6CACJC,IAAI,4BACJC,YAAY,UAASC,YAAAC,EAAA,QAEvBR,EAAAA,cAAA,KAAGS,MAAO,CAAEC,SAAU,SAAUC,MAAO,UAAWC,UAAW,WAAY,0HAK3EZ,EAAAA,cAAA,MAAIE,UAAU,cACZF,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,YAAiB,kIAG3BA,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,wBAA6B,4HAGvCA,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,sBAA2B,qEAKvCA,EAAAA,cAAA,UAAI,oCACJA,EAAAA,cAAA,OAAKE,UAAU,wBACbF,EAAAA,cAACG,EAAAA,EAAW,CACVC,IAAI,4CACJC,IAAI,iCACJC,YAAY,UAASC,YAAAC,EAAA,QAEvBR,EAAAA,cAAA,KAAGS,MAAO,CAAEC,SAAU,SAAUC,MAAO,UAAWC,UAAW,WAAY,gKAK3EZ,EAAAA,cAAA,MAAIE,UAAU,cACZF,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,YAAiB,gIAG3BA,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,wBAA6B,gGAGvCA,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,qBAA0B,iOAOtCA,EAAAA,cAAA,OAAKE,UAAU,wBACbF,EAAAA,cAACG,EAAAA,EAAW,CACVC,IAAI,4CACJC,IAAI,2BACJC,YAAY,UAASC,YAAAC,EAAA,QAEvBR,EAAAA,cAAA,KAAGS,MAAO,CAAEC,SAAU,SAAUC,MAAO,UAAWC,UAAW,WAAY,iFAK3EZ,EAAAA,cAAA,UAAI,sCACJA,EAAAA,cAAA,OAAKE,UAAU,wBACbF,EAAAA,cAACG,EAAAA,EAAW,CACVC,IAAI,4CACJC,IAAI,6BACJC,YAAY,UAASC,YAAAC,EAAA,OAEvBR,EAAAA,cAAA,KAAGS,MAAO,CAAEC,SAAU,SAAUC,MAAO,UAAWC,UAAW,WAAY,gFAI3EZ,EAAAA,cAAA,MAAIE,UAAU,cACZF,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,YAAiB,wGAG3BA,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,wBAA6B,uNAO3CA,EAAAA,cAAA,WAASE,UAAU,WACjBF,EAAAA,cAAA,MAAIE,UAAU,iBAAgB,gDAE9BF,EAAAA,cAAA,UAAI,4CACJA,EAAAA,cAAA,MAAIE,UAAU,cACZF,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,6BAAkC,wLAI5CA,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,2BAAgC,sKAM5CA,EAAAA,cAAA,OAAKE,UAAU,wBACbF,EAAAA,cAACG,EAAAA,EAAW,CACVC,IAAI,6CACJC,IAAI,4BACJC,YAAY,UAASC,YAAAC,EAAA,QAEvBR,EAAAA,cAAA,KAAGS,MAAO,CAAEC,SAAU,SAAUC,MAAO,UAAWC,UAAW,WAAY,wEAK3EZ,EAAAA,cAAA,UAAI,+CACJA,EAAAA,cAAA,MAAIE,UAAU,cACZF,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,mBAAwB,wIAIlCA,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,sBAA2B,wIAGrCA,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,2BAAgC,wLAM5CA,EAAAA,cAAA,OAAKE,UAAU,wBACbF,EAAAA,cAACG,EAAAA,EAAW,CACVC,IAAI,kCACJC,IAAI,iBACJC,YAAY,UAASC,YAAAC,EAAA,QAEvBR,EAAAA,cAAA,KAAGS,MAAO,CAAEC,SAAU,SAAUC,MAAO,UAAWC,UAAW,WAAY,4EAK3EZ,EAAAA,cAAA,OAAKE,UAAU,wBACbF,EAAAA,cAACG,EAAAA,EAAW,CACVC,IAAI,2CACJC,IAAI,kCACJC,YAAY,UAASC,YAAAC,EAAA,QAEvBR,EAAAA,cAAA,KAAGS,MAAO,CAAEC,SAAU,SAAUC,MAAO,UAAWC,UAAW,WAAY,iEAK3EZ,EAAAA,cAAA,UAAI,gDACJA,EAAAA,cAAA,MAAIE,UAAU,cACZF,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,mBAAwB,uLAIlCA,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,wBAA6B,8JAIvCA,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,wBAA6B,gGAKzCA,EAAAA,cAAA,OAAKE,UAAU,wBACbF,EAAAA,cAACG,EAAAA,EAAW,CACVC,IAAI,uCACJC,IAAI,mCACJC,YAAY,UAASC,YAAAC,EAAA,QAEvBR,EAAAA,cAAA,KAAGS,MAAO,CAAEC,SAAU,SAAUC,MAAO,UAAWC,UAAW,WAAY,mFAK3EZ,EAAAA,cAAA,OAAKE,UAAU,wBACbF,EAAAA,cAACG,EAAAA,EAAW,CACVC,IAAI,mCACJC,IAAI,+BACJC,YAAY,UAASC,YAAAC,EAAA,QAEvBR,EAAAA,cAAA,KAAGS,MAAO,CAAEC,SAAU,SAAUC,MAAO,UAAWC,UAAW,WAAY,oDAM7EZ,EAAAA,cAAA,WAASE,UAAU,WACjBF,EAAAA,cAAA,MAAIE,UAAU,iBAAgB,sDAC9BF,EAAAA,cAAA,SAAG,qGAKHA,EAAAA,cAAA,UAAI,kCACJA,EAAAA,cAAA,MAAIE,UAAU,cACZF,EAAAA,cAAA,UAAI,sHAIJA,EAAAA,cAAA,UAAI,gJAMNA,EAAAA,cAAA,UAAI,kCACJA,EAAAA,cAAA,SAAG,6EACHA,EAAAA,cAAA,MAAIE,UAAU,cACZF,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,oBAAyB,2EAGnCA,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,wBAA6B,oHAGvCA,EAAAA,cAAA,UACEA,EAAAA,cAAA,cAAQ,sBAA2B,iGAKvCA,EAAAA,cAAA,OAAKE,UAAU,wBACbF,EAAAA,cAACG,EAAAA,EAAW,CACVC,IAAI,0CACJC,IAAI,6BACJC,YAAY,UAASC,YAAAC,EAAA,OAEvBR,EAAAA,cAAA,KAAGS,MAAO,CAAEC,SAAU,SAAUC,MAAO,UAAWC,UAAW,WAAY,sFAM7EZ,EAAAA,cAAA,WAASE,UAAU,WACjBF,EAAAA,cAAA,MAAIE,UAAU,iBAAgB,2BAC9BF,EAAAA,cAAA,SAAG,sIAKHA,EAAAA,cAAA,UAAI,qEACJA,EAAAA,cAAA,SAAG,2IAKHA,EAAAA,cAAA,UAAI,yDACJA,EAAAA,cAAA,SAAG,8HAKHA,EAAAA,cAAA,UAAI,2DACJA,EAAAA,cAAA,SAAG,iIAKHA,EAAAA,cAAA,UAAI,2DACJA,EAAAA,cAAA,SAAG,wGAKHA,EAAAA,cAAA,UAAI,oDACJA,EAAAA,cAAA,SAAG,2HAMLA,EAAAA,cAAA,WAASE,UAAU,yBACjBF,EAAAA,cAAA,MAAIE,UAAU,iBAAgB,mBAC9BF,EAAAA,cAAA,SAAG,0IAIHA,EAAAA,cAAA,MAAIE,UAAU,cACZF,EAAAA,cAAA,UAAI,oEACJA,EAAAA,cAAA,UAAI,uDACJA,EAAAA,cAAA,UAAI,6EACJA,EAAAA,cAAA,UAAI,6FAShB,C","sources":["webpack://parkinsons-website/./src/pages/silo2.js"],"sourcesContent":["import * as React from \"react\";\nimport Layout from \"../components/layout\";\nimport \"../components/style.css\";\nimport { StaticImage } from \"gatsby-plugin-image\";\n\nexport default function Silo2Page() {\n  return (\n    <Layout>\n      <div className=\"page-container home-page\">\n        <section className=\"hero-section\">\n          <div className=\"hero-text\">\n            <h1>Comprehensive Parkinson's Disease Mechanism Inference Analysis</h1>\n            <p>\n              This project documents a mechanism-based computational framework for Parkinson's\n              disease analysis, analyzing data across two major cohorts: the Parkinson's\n              Progression Markers Initiative (PPMI, n=14,473 patients) and the LRRK2 Consortium\n              (n=2,958 individuals).\n            </p>\n            <p className=\"hero-subtext\">\n              The goal was to shift the paradigm from classifying patients merely by symptoms\n              to inferring underlying biological pathway dysfunctions.\n            </p>\n          </div>\n        </section>\n\n        <section className=\"section\">\n          <h2 className=\"section-title\">I. Foundational Methodology and Research Rigor</h2>\n          <p>Our methodology focused on mechanism inference.</p>\n\n          <h3>Paradigm Shift to Mechanisms</h3>\n          <p>\n            We moved beyond traditional symptom-based classification (e.g., \"tremor-dominant PD\")\n            to identify the specific biological pathway dysfunctions (such as dopaminergic\n            degeneration or LRRK2 kinase activity) causing observed clinical manifestations.\n          </p>\n\n          <h3>Biological Pathways Analyzed</h3>\n          <p>The analysis covered 5 major categories implicated in PD pathogenesis:</p>\n          <ul className=\"tight-list\">\n            <li>Pathway 01: Dopaminergic Degeneration & Motor Control (Nigrostriatal tract)</li>\n            <li>Pathway 02: Genetic & Molecular Mechanisms (LRRK2 kinase, α-Synuclein pathology)</li>\n            <li>Pathway 03: Cholinergic & Cognitive Control (Olfaction, cognition, sleep disorders)</li>\n            <li>Pathway 06: Gait Dynamics & Wearable Sensors (Objective kinematic measures)</li>\n            <li>Pathway 08: Cross-Pathway Integration (Multimodal characterization)</li>\n          </ul>\n\n          <h3>Advanced Clustering Technique</h3>\n          <p>\n            We employed a Bayesian Gaussian Mixture Model (B-GMM) with a Dirichlet Process Prior\n            to automatically determine the optimal number of patient subgroups (phenotypes) based\n            on statistical criteria, such as the lowest Bayesian Information Criterion (BIC).\n          </p>\n\n          <h3>Compliance</h3>\n          <p>\n            We maintained complete data integrity by strictly enforcing NO data imputation; only\n            actual measured values were analyzed. All 36 evidence-based research claims are\n            supported by complete code-to-result traceability.\n          </p>\n        </section>\n\n        <section className=\"section\">\n          <h2 className=\"section-title\">II. Major Verified Findings (Tier 1 Discoveries)</h2>\n          <p>\n            The analysis generated 36 verified claims. The following are the most clinically\n            significant discoveries:\n          </p>\n\n          <h3>1. Genetic Risk Quantification: LRRK2 G2019S</h3>\n          <div className=\"progressive-ai-image\">\n            <StaticImage\n              src=\"../images/02_lrrk2_penetrance_analysis.png\"\n              alt=\"LRRK2 Penetrance Analysis\"\n              placeholder=\"blurred\"\n            />\n            <p style={{ fontSize: '0.9rem', color: '#726657', marginTop: '0.5rem' }}>\n              Figure 1: LRRK2 Penetrance Analysis demonstrating difference in PD prevalence\n              between LRRK2 carriers and non-carriers\n            </p>\n          </div>\n          <ul className=\"tight-list\">\n            <li>\n              <strong>Finding:</strong> The LRRK2 G2019S mutation confers a 1.89-fold increased\n              risk for Parkinson's disease in the LRRK2 Consortium cohort (n=2,958)\n            </li>\n            <li>\n              <strong>Supporting Evidence:</strong> 49.7% of LRRK2-positive carriers developed PD\n              (805/1,620), compared to 26.3% of LRRK2-negative non-carriers (352/1,338)\n            </li>\n            <li>\n              <strong>Statistical Proof:</strong> The association is highly significant\n              (χ² = 167.263, p &lt; 0.001)\n            </li>\n          </ul>\n\n          <h3>2. Motor Phenotype Heterogeneity</h3>\n          <div className=\"progressive-ai-image\">\n            <StaticImage\n              src=\"../images/01_motor_phenotype_clusters.png\"\n              alt=\"Motor Phenotype Clusters (PCA)\"\n              placeholder=\"blurred\"\n            />\n            <p style={{ fontSize: '0.9rem', color: '#726657', marginTop: '0.5rem' }}>\n              Figure 2: Motor Phenotype Clusters - 4,166 patients plotted in 2D space (PCA) with\n              71.7% variance preserved, visually confirming separation of 5 phenotypes\n            </p>\n          </div>\n          <ul className=\"tight-list\">\n            <li>\n              <strong>Finding:</strong> Unsupervised clustering of 4,166 baseline UPDRS-III motor\n              assessments identified 5 distinct motor phenotypes in PD patients\n            </li>\n            <li>\n              <strong>Supporting Evidence:</strong> The clusters demonstrated moderate-good\n              separation validated by a Silhouette Score of 0.535\n            </li>\n            <li>\n              <strong>Clinical Profile:</strong> The phenotypes showed a clear severity gradient,\n              ranging from the largest cluster (47.4%, Minimal/Early-stage, mean UPDRS=2.49) to\n              the smallest, most severely impaired cluster (3.1%, Severe impairment, mean\n              UPDRS=34.61)\n            </li>\n          </ul>\n\n          <div className=\"progressive-ai-image\">\n            <StaticImage\n              src=\"../images/07_motor_phenotype_profiles.png\"\n              alt=\"Motor Phenotype Profiles\"\n              placeholder=\"blurred\"\n            />\n            <p style={{ fontSize: '0.9rem', color: '#726657', marginTop: '0.5rem' }}>\n              Figure 3: Motor Phenotype Profiles showing mean subscale scores by phenotype\n            </p>\n          </div>\n\n          <h3>3. Prodromal Olfactory Dysfunction</h3>\n          <div className=\"progressive-ai-image\">\n            <StaticImage\n              src=\"../images/03_moca_upsit_distributions.png\"\n              alt=\"MoCA & UPSIT Distributions\"\n              placeholder=\"blurred\"\n            />\n            <p style={{ fontSize: '0.9rem', color: '#726657', marginTop: '0.5rem' }}>\n              Figure 4: MoCA & UPSIT Distributions highlighting 50.2% hyposmia prevalence\n            </p>\n          </div>\n          <ul className=\"tight-list\">\n            <li>\n              <strong>Finding:</strong> 50.2% of the assessed cohort (n=5,122) exhibited olfactory\n              dysfunction (hyposmia, UPSIT score &lt; 25)\n            </li>\n            <li>\n              <strong>Mechanism Inference:</strong> This high prevalence confirms hyposmia as a\n              major prodromal marker for PD, indicating α-synuclein pathology has reached the\n              olfactory bulb (Braak Stage 1-2) before substantial dopaminergic neuron death occurs\n            </li>\n          </ul>\n        </section>\n\n        <section className=\"section\">\n          <h2 className=\"section-title\">III. Key Findings Across Biological Pathways</h2>\n\n          <h3>Pathway 01: Dopaminergic & Motor Control</h3>\n          <ul className=\"tight-list\">\n            <li>\n              <strong>LRRK2 and Motor Severity:</strong> LRRK2-positive carriers (n=1,507) exhibit\n              49% worse motor severity (mean UPDRS3 = 12.47) compared to LRRK2-negative\n              non-carriers (mean UPDRS3 = 8.36, p &lt; 0.001, Cohen's d = 0.304)\n            </li>\n            <li>\n              <strong>Gait-Motor Correlation:</strong> Objectively measured gait speed (SP_U)\n              negatively correlates with clinically assessed motor severity (UPDRS-III total,\n              Spearman r = -0.301, p = 0.000079, n=166)\n            </li>\n          </ul>\n\n          <div className=\"progressive-ai-image\">\n            <StaticImage\n              src=\"../images/06_gait_motor_stratification.png\"\n              alt=\"Gait-Motor Stratification\"\n              placeholder=\"blurred\"\n            />\n            <p style={{ fontSize: '0.9rem', color: '#726657', marginTop: '0.5rem' }}>\n              Figure 5: Gait Speed vs Motor Severity showing negative correlation\n            </p>\n          </div>\n\n          <h3>Pathway 03: Cholinergic & Cognitive Control</h3>\n          <ul className=\"tight-list\">\n            <li>\n              <strong>RBD Prevalence:</strong> 37.5% of assessed patients (n=1,548) were\n              RBD-positive, indicating specific brainstem α-synucleinopathy affecting REM sleep\n              control\n            </li>\n            <li>\n              <strong>Cognitive Decline:</strong> 25.9% of patients (n=13,835) scored below the MCI\n              threshold (MoCA &lt; 26), reflecting degeneration in the cholinergic basal forebrain\n            </li>\n            <li>\n              <strong>Multimodal Correlation:</strong> Positive correlation between MoCA cognitive\n              scores and UPSIT olfactory scores (r = 0.165, p &lt; 0.001, n=5,063), supporting the\n              hypothesis of shared α-synuclein pathological spread\n            </li>\n          </ul>\n\n          <div className=\"progressive-ai-image\">\n            <StaticImage\n              src=\"../images/04_rbd_prevalence.png\"\n              alt=\"RBD Prevalence\"\n              placeholder=\"blurred\"\n            />\n            <p style={{ fontSize: '0.9rem', color: '#726657', marginTop: '0.5rem' }}>\n              Figure 6: RBD Prevalence showing proportion of RBD-positive individuals\n            </p>\n          </div>\n\n          <div className=\"progressive-ai-image\">\n            <StaticImage\n              src=\"../images/08_multimodal_correlations.png\"\n              alt=\"Cognitive-Olfactory Correlation\"\n              placeholder=\"blurred\"\n            />\n            <p style={{ fontSize: '0.9rem', color: '#726657', marginTop: '0.5rem' }}>\n              Figure 7: Cognitive-Olfactory Correlation (r=0.165, p&lt;0.001)\n            </p>\n          </div>\n\n          <h3>Pathway 06: Gait Dynamics & Wearable Sensors</h3>\n          <ul className=\"tight-list\">\n            <li>\n              <strong>Dual-Task Cost:</strong> Gait speed significantly degrades under cognitive\n              load with a mean dual-task cost of 14.87% (t = 14.984, p &lt; 0.001, n=172),\n              evidencing cognitive-motor network integration failure\n            </li>\n            <li>\n              <strong>Arm Swing Asymmetry:</strong> Using IMU sensors, 27.0% of patients (n=178)\n              exhibited clinically significant asymmetry (&gt;20%), supporting lateralized\n              dopaminergic neuron loss mechanism\n            </li>\n            <li>\n              <strong>Mobility Impairment:</strong> 29.0% of patients (n=186) were classified as\n              mobility impaired (TUG duration &gt; 12 seconds)\n            </li>\n          </ul>\n\n          <div className=\"progressive-ai-image\">\n            <StaticImage\n              src=\"../images/05_arm_swing_asymmetry.png\"\n              alt=\"Arm Swing Asymmetry Distribution\"\n              placeholder=\"blurred\"\n            />\n            <p style={{ fontSize: '0.9rem', color: '#726657', marginTop: '0.5rem' }}>\n              Figure 8: Arm Swing Asymmetry Distribution highlighting 20% clinical threshold\n            </p>\n          </div>\n\n          <div className=\"progressive-ai-image\">\n            <StaticImage\n              src=\"../images/09_tug_performance.png\"\n              alt=\"TUG Performance Distribution\"\n              placeholder=\"blurred\"\n            />\n            <p style={{ fontSize: '0.9rem', color: '#726657', marginTop: '0.5rem' }}>\n              Figure 9: TUG Performance Distribution (n=186)\n            </p>\n          </div>\n        </section>\n\n        <section className=\"section\">\n          <h2 className=\"section-title\">IV. Multimodal Biomarkers and Clinical Translation</h2>\n          <p>\n            The project's ultimate objective is enabling precision medicine by integrating multiple\n            findings.\n          </p>\n\n          <h3>Objective Biomarker Validation</h3>\n          <ul className=\"tight-list\">\n            <li>\n              Phospho-S1292-LRRK2 in urinary exosomes (n=884) documented as a pharmacodynamic\n              marker for LRRK2 inhibitor therapy\n            </li>\n            <li>\n              CSF α-Synuclein Seed Amplification Assay (CSFSAA) status assessed in 145 samples,\n              useful for differentiating PD from atypical parkinsonisms\n            </li>\n          </ul>\n\n          <h3>Clinical Translation Readiness</h3>\n          <p>The quantified findings directly support immediate clinical applications:</p>\n          <ul className=\"tight-list\">\n            <li>\n              <strong>Genetic Testing:</strong> Precise risk quantification (1.89×) informs LRRK2\n              screening guidelines\n            </li>\n            <li>\n              <strong>Prodromal Screening:</strong> High prevalence of hyposmia (50.2%) and RBD\n              (37.5%) provides clear targets for early detection and intervention\n            </li>\n            <li>\n              <strong>Motor Phenotyping:</strong> The 5 identified motor subtypes enable selection\n              of stratified, pathway-specific treatments\n            </li>\n          </ul>\n\n          <div className=\"progressive-ai-image\">\n            <StaticImage\n              src=\"../images/10_clusters_well_measured.png\"\n              alt=\"Additional Clustering View\"\n              placeholder=\"blurred\"\n            />\n            <p style={{ fontSize: '0.9rem', color: '#726657', marginTop: '0.5rem' }}>\n              Figure 10: Additional clustering visualization for Dopaminergic Pathway analysis\n            </p>\n          </div>\n        </section>\n\n        <section className=\"section\">\n          <h2 className=\"section-title\">Complete Claims Summary</h2>\n          <p>\n            This comprehensive analysis documents 36 evidence-based research claims organized\n            across five major biological pathway categories:\n          </p>\n\n          <h3>Pathway 01: Dopaminergic Degeneration & Motor Control (15 Claims)</h3>\n          <p>\n            Including motor phenotype identification, LRRK2 motor severity effects, gait-motor\n            correlations, and longitudinal tracking capabilities\n          </p>\n\n          <h3>Pathway 02: Genetic & Molecular Mechanisms (4 Claims)</h3>\n          <p>\n            Covering LRRK2 genetic risk quantification, phospho-LRRK2 biomarkers, CSFSAA status\n            assessment, and α-synuclein modulation\n          </p>\n\n          <h3>Pathway 03: Cholinergic & Cognitive Control (10 Claims)</h3>\n          <p>\n            Addressing cognitive impairment prevalence, olfactory dysfunction, RBD prevalence,\n            dual-task costs, and autonomic dysfunction\n          </p>\n\n          <h3>Pathway 06: Gait Dynamics & Wearable Sensors (4 Claims)</h3>\n          <p>\n            Quantifying arm swing asymmetry, stride time variability, TUG performance, and\n            dual-task degradation\n          </p>\n\n          <h3>Pathway 08: Cross-Pathway Integration (3 Claims)</h3>\n          <p>\n            Synthesizing cognitive-olfactory correlations, multimodal cohort characterization, and\n            LRRK2+ multi-phenotype profiles\n          </p>\n        </section>\n\n        <section className=\"section final-callout\">\n          <h2 className=\"section-title\">Clinical Impact</h2>\n          <p>\n            This mechanism-based computational framework shifts PD analysis from symptom\n            classification to biological pathway inference, enabling:\n          </p>\n          <ul className=\"tight-list\">\n            <li>Precise genetic risk stratification for clinical decision-making</li>\n            <li>Early detection through validated prodromal markers</li>\n            <li>Personalized treatment strategies based on motor phenotype classification</li>\n            <li>\n              Objective, quantitative biomarkers for remote monitoring and clinical trial\n              enrichment\n            </li>\n          </ul>\n        </section>\n      </div>\n    </Layout>\n  );\n}\n"],"names":["Silo2Page","React","Layout","className","StaticImage","src","alt","placeholder","__imageData","require","style","fontSize","color","marginTop"],"sourceRoot":""}